Selected A-share Announcements | It is rumored that Talkweb Information System (002261.SZ) is planning to adjust its major asset restructuring plan. The company denies the information as untrue!

Today's Focus 1. Talkweb Information System: Rumors of "Company Plans to Adjust Major Asset Restructuring Plan" are False Information Talkweb Information System has issued a clarification announcement stating that they are aware of rumors circulating online that the company plans to adjust a major asset restructuring plan. The company and the board of directors are highly concerned about this and to avoid misleading the public and investors, they are clarifying that the above-mentioned rumor is false information. As of the date of this announcement, the company does not have any major asset restructuring plans in progress, including but not limited to acquisitions, debt restructuring, business restructuring, asset divestments, asset injections, bankruptcy reorganizations, major business collaborations, introduction of strategic investors, etc. There are no issues that would have a significant impact on the company's stock price, and no major information that should be disclosed but has not been. The company reserves the right to pursue legal action against any media or platform that publishes, reprints, or spreads unverified content that affects the company. 2. Beijing Dabeinong Technology Group: February Pig Sales Revenue of 726 million RMB Beijing Dabeinong Technology Group (002385) disclosed a brief report on pig sales in February. The total number of pigs sold by the company's controlling and shareholding companies in February was 475,800, totaling 1.17 million in January and February. The total sales revenue in February was 726 million RMB, totaling 1.909 billion RMB in January and February. The average price of commercial pigs in February for the company's controlling and shareholding companies was 14.08 RMB per kilogram. 3. Chifeng Jilong Gold Mining: H Share Public Offering Price of 13.72 Hong Kong Dollars per Share Chifeng Jilong Gold Mining (600988.SH) announced that the company is conducting an overseas listing of shares (H shares) and will be listed on the main board of the Hong Kong Stock Exchange. The final price for this H share issuance has been determined to be 13.72 Hong Kong Dollars per share. The H shares are expected to be listed on the main board of the Hong Kong Stock Exchange on March 10, 2025, and begin trading. 4. China Resources Double-Crane Pharmaceutical: Subsidiary's Zhejiang Xinsaike Losartan Raw Material Drug Receives Approval for Market Application China Resources Double-Crane Pharmaceutical (600062.SH) announced that its subsidiary Zhejiang Xinsaike has received the "Notice of Approval for Market Application of Chemical Raw Material Drug" from the National Medical Products Administration for its Losartan raw material drug. The raw material drug has met the relevant national drug evaluation technical standards and can be produced and sold in the domestic market after passing GMP compliance inspection, which will help enrich the company's product line and enhance market competitiveness. However, the production and future sales of this raw material drug may be affected by factors such as changes in national policies and market conditions, leading to some uncertainties. 5. Guangzhou Baiyunshan Pharmaceutical Holdings: Subsidiary Receives Approval for Market Application of Atorvastatin Calcium Raw Material Drug Guangzhou Baiyunshan Pharmaceutical Holdings (600332.SH) announced that its subsidiary, Guangzhou Baiyunshan Pharmaceutical Holdings Chemical Pharmaceutical Factory, has received the "Notice of Approval for Market Application of Atorvastatin Calcium Chemical Raw Material Drug" issued by the National Medical Products Administration. Atorvastatin calcium is an HMG-CoA reductase inhibitor mainly used to treat conditions such as high cholesterol. The approval of this raw material drug will help enrich the product line of Guangzhou Baiyunshan Pharmaceutical Holdings Chemical Pharmaceutical Factory in the cardiovascular and cerebrovascular category, but it will not have a significant impact on the company's current performance. 6. Jiangsu Hengrui Pharmaceuticals: Subsidiary Receives Approval for Drug Clinical Trial Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiaries, Suzhou Shengdiya Biomedical Pharmaceutical Co., Ltd. and Shanghai Shengdi Pharmaceutical Co., Ltd., have received the "Approval Notice for Drug Clinical Trial" for injection SHR-A1811, Bevacizumab Injection, Atezolizumab Injection, and SHR-8068 Injection issued by the National Medical Products Administration. Clinical trials will be conducted in the near future. Among them, the combination therapy of injection SHR-A1811 for the treatment of advanced solid tumors will undergo an open, multicenter Phase Ib/II clinical study. 7. JD HEALTH: Total Revenue for the Full Year 2024 Reaches 58.2 Billion RMB, Core Metrics Exceed Market Expectations JD HEALTH (6618.HK) released its full-year performance announcement for 2024 on March 6. According to the announcement, JD HEALTH's total revenue in 2024 reached 58.2 billion RMB, with a non-IFRS net profit of 4.79 billion RMB, both exceeding market expectations. Especially in the second half of 2024, JD HEALTH achieved faster growth in revenue with a "double-digit" increase year-on-year, showing strong development momentum. During the reporting period, JD HEALTH made several innovative breakthroughs in areas such as pharmaceutical retail and medical services, expanding its market share in core categories such as pharmaceuticals, while increasing user stickiness and expanding its social and industry value effects. In 2025, JD HEALTH is expected to continue its steady growth momentum, benefiting shareholders and investors.Investors create value.8. Orient Group Incorporation: Risks of major violations leading to forced delisting and failure to meet restructuring conditions Orient Group Incorporation (600811.SH) announced that the company's stock trading has experienced abnormal fluctuations, with the closing price deviating by more than 20% for two consecutive trading days. The company faces the risk of major violations leading to forced delisting, as it is under investigation by the China Securities Regulatory Commission for suspected serious financial fraud, which may trigger the situation of major violations leading to forced delisting. In addition, the company faces the risk of not meeting the conditions for restructuring, as it has been under investigation and may trigger the situation of major violations leading to forced delisting, which does not comply with the provisions on restructuring value in the minutes of the working symposium on effectively handling bankruptcy and restructuring cases of listed companies issued by the Supreme People's Court and the China Securities Regulatory Commission. The company also faces the problem of being unable to repay the raised funds on time. Investors are advised to pay attention to investment risks. 9. Shenzhen Zowee Technology: No undisclosed material information Shenzhen Zowee Technology (002369.SZ) issued a statement on the abnormal fluctuations in stock trading, stating that the company's stock price has deviated by more than 20% for three consecutive trading days since March 4, 2025, which is considered abnormal stock trading. Upon verification, there is no need to correct or supplement the information previously disclosed by the company, and there have been no significant changes in the recent operating conditions and internal and external operating environments. The controlling shareholder and actual controller have no undisclosed material information about the company. The cumulative increase in the company's stock price is significant, and investors are advised to make rational decisions and be aware of investment risks. 10. Hangzhou Advance Gearbox Group: Risks of overheated market sentiment and significant short-term decline in stock prices Hangzhou Advance Gearbox Group (601177.SH) issued a statement on the abnormal fluctuations in stock trading, stating that the company's stock price has deviated by more than 20% for three consecutive trading days, which is considered abnormal stock trading. In addition, the company's stock price has shown the same abnormal fluctuations in four out of ten consecutive trading days, with a cumulative increase of 147.14%, posing the risks of overheated market sentiment and significant short-term decline. Upon verification, the company's current production and operation situation is normal, and there is no undisclosed significant information. The company's main business is the design, manufacturing, and sales of various types of gear transmission devices, and there will be no significant changes in the short term. 11. Shanghai Fudan Forward S&T: Termination of acquiring 51% equity of Meilirensheng Company Shanghai Fudan Forward S&T (600624) announced that the company originally planned to use self-financed funds to invest 114.1 million yuan to acquire 51% equity of Ningbo Meilirensheng Pharmaceutical Biotechnology Development Co., Ltd. ("Meilirensheng"), and has signed the "Equity Acquisition Agreement of Ningbo Meilirensheng Pharmaceutical Biotechnology Development Co., Ltd." On February 25, 2025, the company received the ruling of the Shanghai International Economic and Trade Arbitration Commission (Shanghai International Arbitration Center) on the "Dispute Arbitration on the Equity Acquisition Agreement of Ningbo Meilirensheng Pharmaceutical Biotechnology Development Co., Ltd." (), in which the Shanghai International Arbitration Commission ruled that the "Equity Acquisition Agreement" in question had been established but had not yet taken effect. In view of the above situation, to protect the interests of the company and investors, the company decided to terminate the acquisition of 51% equity of Ningbo Meilirensheng Pharmaceutical Biotechnology Development Co., Ltd. 12. Jiayu Holding: Controlling shareholder's 35.78% stake in the company may be auctioned off judicially Jiayu Holding (300117) announced that due to a contract dispute between Henan Xinye Enterprise Management Partnership Enterprise (Limited Partnership) and Jiayu Group, the Intermediate People's Court of Zhengzhou, Henan Province, will conduct a public auction of 854.87 million shares held by Jiayu Group, the controlling shareholder of the company, on the judicial auction network platform of JD.com from 10:00 on April 3 to 10:00 on April 4. Subsequently, the remaining 248 million shares held by Jiayu Group in the company will continue to be disposed of through online judicial auctions. The shares that may be auctioned off this time account for 94.15% of the total number of shares held by Jiayu Group in the company, representing 35.78% of the total share capital of the company. This judicial auction may lead to a change in the company's controlling rights or the first largest shareholder. 13. Hubei Donper Electromechanical Group: Plans to invest 2 billion yuan to build a high-end frequency conversion intelligent manufacturing base project Hubei Donper Electromechanical Group (601956) announced that its subsidiary, Huangshi Dongbei Compressor Co., Ltd., plans to invest approximately 2 billion yuan to build a high-end frequency conversion intelligent manufacturing base project, including a new intelligent flat compresso6. SH) Announcement: The company signed a strategic cooperation framework agreement on the Alashan Hydrogen Production and Green Energy Integration Project with the Alashan League Administration Bureau on March 6, 2025. The project is expected to have a total investment of approximately 19.36 billion yuan, to be implemented in two phases, with the first phase expected to have an investment of 2.48 billion yuan, and the second phase expected to have an investment of 16.88 billion yuan. The main construction content of the project includes the construction of a 1.5 billion Nm/a electrolyzed water hydrogen production unit, a 300,000 ton/year green methanol production unit, a 600,000 ton/year green synthetic ammonia production unit, and green replacement projects for traditional industries. This agreement is only a framework agreement for the strategic cooperation between the two parties and does not have legal binding force. There is uncertainty in the specific cooperation matters and implementation progress.Catalyst Group30005000The Catalyst Holding Group plans to use its own funds and/or self-raised funds (including stock holding loans provided by the CITIC BANK Dalian Branch) to increase its stake in the company through the trading system allowed by the Shanghai Stock Exchange within 12 months starting from March 7, 2025 (including but not limited to centralized bidding, block trading, or other ways that comply with relevant laws and regulations), with the total amount of the increase not less than 30 million yuan and not more than 50 million yuan.The resignation report will take effect from the date it is delivered to the board of directors.Hangzhou Haoyue Personal Care: plans to purchase assets of 266 million yuan from Nantong Da Wang Hangzhou Haoyue Personal Care (605009) announced that the company has signed an "Asset Transfer Agreement" with Nantong Da Wang Household Products Co., Ltd. (referred to as "Nantong Da Wang") with a transaction amount of 266 million yuan. After purchasing the assets this time, Nantong Da Wang's GOO.N brand baby diapers production business will be entrusted to external companies such as Hangzhou Haoyue Personal Care. In addition, the company plans to invest in establishing Hangzhou Haoyue Personal Care Products (Nantong) Co., Ltd. (referred to as the "project company") in Nantong Economic and Technological Development Zone, Jiangsu Province, with a total investment of no more than 400 million yuan within three years. The project company will purchase, through cash payment, the land use area of 84,000 square meters, factory building area of 67,800 square meters, and 11 baby diaper production related equipment held by Nantong Da Wang in the West Zone (the first factory) of Nantong Economic and Technological Development Zone, Jiangsu Province. This article is reproduced from "Tencent Stock Selection", edited by GMTEight: Xu Wenqiang.